Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps

Sorrento plans to begin a phase II study in the first half of 2020 on ZTlido 5.4% for chronic low back pain. Scilex's other lead compound SP-102 has …
Source: back pain